Table of Content


Chapter 1 Methodology
1.1 Market definitions
1.2 Base estimates & working
1.3 Forecast parameters
1.4 Data validation
1.5 Data sources
1.5.1 Secondary
1.5.1.1 Paid sources
1.5.1.2 Unpaid sources
1.5.2 Primary
Chapter 2 Executive Summary
2.1 Biosimilars industry 360 degree synopsis, 2017-2030 (USD Million)
2.1.1 Business trends
2.1.2 Product trends
2.1.3 Application trends
2.1.4 Manufacturer trends
2.1.5 Technology trends
2.1.6 Regional trends
Chapter 3 Biosimilars Industry Insights
3.1 Industry segmentation
3.2 Industry landscape, 2017-2030 (USD Million)
3.3 Industry impact factors
3.3.1 Growth drivers
3.3.1.1 Strong product pipeline
3.3.1.2 Rise in prevalence of chronic diseases across the globe
3.3.1.3 Expiry of blockbuster biologics
3.3.1.4 Cost-effectiveness of biosimilars
3.3.1.5 Recent biosimilar product approvals in major countries
3.3.2 Industry pitfalls & challenges
3.3.2.1 Availability of alternative medications
3.3.2.2 Regulatory Uncertainty
3.3.2.3 High developmental costs
3.3.2.4 Complex manufacturing process
3.4 Growth potential analysis
3.4.1 By product
3.4.2 By application
3.4.3 By manufacturer
3.4.4 By technology
3.5 COVID-19 impact analysis
3.6 PORTER’s Analysis
3.7 Regulatory landscape
3.7.1 U.S.
3.7.2 Canada
3.7.3 Europe
3.7.4 India
3.7.5 Japan
3.7.6 South Korea
3.7.7 Australia
3.7.8 Singapore
3.8 Reimbursement landscape
3.8.1 U.S.
3.8.2 Europe
3.8.3 Canada
3.8.4 Australia
3.8.5 New Zealand
3.9 Market analysis
3.9.1 Strength
3.9.2 Weakness
3.9.3 Opportunity
3.9.4 Threat
3.10 U.S. biosimilars insurance coverage, 2021
3.11 Biosimilar litigation landscape
3.12 Biosimilar product pipeline analysis
3.12.1 Amgen
3.12.2 Biocon
3.12.3 Sandoz
3.12.4 Celltrion
3.12.5 Coherus BioSciences
3.12.6 Fresenius Kabi
3.12.7 Pfizer
3.12.8 Lupin
3.12.9 Samsung Bioepis
3.12.10 Teva Pharmaceuticals
3.13 Biosimilars approval scenario, 2017-2022
3.13.1 U.S.
3.13.2 Canada
3.13.3 Europe
3.13.4 India
3.13.5 South Korea
3.13.6 Australia
3.13.7 New Zealand
3.13.8 Singapore
3.13.9 Malaysia
3.14 Biologics patent expiry scenario
3.15 Biosimilars industry evolution
3.16 Biosimilars factor analysis
3.16.1 Access
3.16.2 Regulations
3.16.3 Payer assessment and access
3.16.4 Physician acceptance
3.16.5 Patient acceptance
3.16.6 Number of biosimilar approvals
3.17 Biosimilars landscape - country analysis
3.17.1 U.S.
3.17.2 Europe
3.17.3 China
3.17.4 Japan
3.17.5 India
3.17.6 South Korea
3.18 Key market success factors
3.19 International policies on use of biosimilar drugs
3.19.1 Interchangeability, Switching and Substitution
3.19.2 Supply Side Policies
3.19.3 Prescribing Incentives
3.20 Competitive landscape, 2021
3.20.1 Competitive matrix analysis, 2021
3.21 PESTEL analysis
Chapter 4 Biosimilars Market, By Product
4.1 Key segment trends
4.2 Recombinant Non-Glycosylated Proteins
4.2.1 Market size, by region, 2017-2030 (USD Million)
4.2.2 Human Growth Hormone
4.2.2.1 Market size, by region, 2017-2030 (USD Million)
4.2.3 Granulocyte Colony-Stimulating Factor (Filgrastim)
4.2.3.1 Market size, by region, 2017-2030 (USD Million)
4.2.4 Insulin
4.2.4.1 Market size, by region, 2017-2030 (USD Million)
4.2.5 Interferon
4.2.5.1 Market size, by region, 2017-2030 (USD Million)
4.2.5.2 Alfa
4.2.5.2.1 Market size, by region, 2017-2030 (USD Million)
4.2.5.3 Beta
4.2.5.3.1 Market size, by region, 2017-2030 (USD Million)
4.3 Recombinant Glycosylated Proteins
4.3.1 Market size, by region, 2017-2030 (USD Million)
4.3.2 Erythropoietin
4.3.2.1 Market size, by region, 2017-2030 (USD Million)
4.3.2.2 Alfa
4.3.2.2.1 Market size, by region, 2017-2030 (USD Million)
4.3.2.3 Zeta
4.3.2.3.1 Market size, by region, 2017-2030 (USD Million)
4.3.3 Monoclonal Antibodies
4.3.3.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.2 Infliximab
4.3.3.2.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.3 Rituximab
4.3.3.3.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.4 Adalimumab
4.3.3.4.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.5 Trastuzumab
4.3.3.5.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.6 Bevacizumab
4.3.3.6.1 Market size, by region, 2017-2030 (USD Million)
4.3.3.7 Etanercept
4.3.3.7.1 Market size, by region, 2017-2030 (USD Million)
4.3.4 Follitropin
4.3.4.1 Market size, by region, 2017-2030 (USD Million)
4.3.4.2 Alfa
4.3.4.2.1 Market size, by region, 2017-2030 (USD Million)
4.3.4.3 Beta
4.3.4.3.1 Market size, by region, 2017-2030 (USD Million)
4.3.5 Low Molecular Weight Heparin (LMWHs)
4.3.5.1 Market size, by region, 2017-2030 (USD Million)
Chapter 5 Biosimilars Market, By Application
5.1 Key segment trends
5.2 Hematology
5.2.1 Market size, by region, 2017-2030 (USD Million)
5.2.2 Neutropenia
5.2.2.1 Market size, by region, 2017-2030 (USD Million)
5.2.3 Anemia
5.2.3.1 Market size, by region, 2017-2030 (USD Million)
5.2.4 Others
5.2.4.1 Market size, by region, 2017-2030 (USD Million)
5.3 Oncology
5.3.1 Market size, by region, 2017-2030 (USD Million)
5.3.2 Lung Cancer
5.3.2.1 Market size, by region, 2017-2030 (USD Million)
5.3.3 Brain Cancer
5.3.3.1 Market size, by region, 2017-2030 (USD Million)
5.3.4 Breast Cancer
5.3.4.1 Market size, by region, 2017-2030 (USD Million)
5.3.5 Cervical Cancer
5.3.5.1 Market size, by region, 2017-2030 (USD Million)
5.3.6 Colorectal Cancer
5.3.6.1 Market size, by region, 2017-2030 (USD Million)
5.3.7 Leukemia
5.3.7.1 Market size, by region, 2017-2030 (USD Million)
5.3.7.2 Non-Hodgkin Lymphoma (NHL)
5.3.7.2.1 Market size, by region, 2017-2030 (USD Million)
5.3.7.3 Chronic Lymphocytic Leukemia (CLL)
5.3.7.3.1 Market size, by region, 2017-2030 (USD Million)
5.3.7.4 Others
5.3.7.4.1 Market size, by region, 2017-2030 (USD Million)
5.3.8 Others
5.3.8.1 Market size, by region, 2017-2030 (USD Million)
5.4 Autoimmune Disease
5.4.1 Market size, by region, 2017-2030 (USD Million)
5.4.2 Arthritis
5.4.2.1 Market size, by region, 2017-2030 (USD Million)
5.4.2.2 Rheumatoid Arthritis
5.4.2.2.1 Market size, by region, 2017-2030 (USD Million)
5.4.2.3 Psoriatic Arthritis
5.4.2.3.1 Market size, by region, 2017-2030 (USD Million)
5.4.2.4 Juvenile Arthritis
5.4.2.4.1 Market size, by region, 2017-2030 (USD Million)
5.4.2.5 Ankylosing Spondylitis
5.4.2.5.1 Market size, by region, 2017-2030 (USD Million)
5.4.2.6 Others
5.4.2.6.1 Market size, by region, 2017-2030 (USD Million)
5.4.3 Inflammatory Bowel Disease (IBD)
5.4.3.1 Market size, by region, 2017-2030 (USD Million)
5.4.3.2 Ulcerative Colitis
5.4.3.2.1 Market size, by region, 2017-2030 (USD Million)
5.4.3.3 Crohn’s Disease
5.4.3.3.1 Market size, by region, 2017-2030 (USD Million)
5.4.3.4 Others
5.4.3.4.1 Market size, by region, 2017-2030 (USD Million)
5.4.4 Psoriasis
5.4.4.1 Market size, by region, 2017-2030 (USD Million)
5.4.5 Others
5.4.5.1 Market size, by region, 2017-2030 (USD Million)
5.5 Growth Hormone Deficiency
5.5.1 Market size, by region, 2017-2030 (USD Million)
5.6 Diabetes
5.6.1 Market size, by region, 2017-2030 (USD Million)
5.7 Others
5.7.1 Market size, by region, 2017-2030 (USD Million)
Chapter 6 Biosimilars Market, By Manufacturer
6.1 Key segment trends
6.2 Contract Research and Manufacturing Services
6.2.1 Market size, by region, 2017-2030 (USD Million)
6.3 In-house
6.3.1 Market size, by region, 2017-2030 (USD Million)
Chapter 7 Biosimilars Market, By Technology
7.1 Key segment trends
7.2 Recombinant DNA Technology (rDNA technology)
7.2.1 Market size, by region, 2017-2030 (USD Million)
7.3 Monoclonal Antibodies (MAb) Technology
7.3.1 Market size, by region, 2017-2030 (USD Million)
Chapter 8 Biosimilars Market, By Region
8.1 Key regional trends
8.2 North America
8.2.1 Market size, by country, 2017-2030 (USD Million)
8.2.2 Market size, by product, 2017-2030 (USD Million)
8.2.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.2.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.2.2.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.2.3 Market size, by application, 2017-2030 (USD Million)
8.2.3.1 Market size, by hematology, 2017-2030 (USD Million)
8.2.3.2 Market size, by oncology, 2017-2030 (USD Million)
8.2.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.2.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.2.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.2.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.2.4 Market size, by manufacturer, 2017-2030 (USD Million)
8.2.5 Market size, by technology, 2017-2030 (USD Million)
8.2.6 U.S.
8.2.6.1 Market size, by product, 2017-2030 (USD Million)
8.2.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.2.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.2.6.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.2.6.2 Market size, by application, 2017-2030 (USD Million)
8.2.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.2.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.2.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.2.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.2.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.2.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.2.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.2.6.4 Market size, by technology, 2017-2030 (USD Million)
8.2.7 Canada
8.2.7.1 Market size, by product, 2017-2030 (USD Million)
8.2.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.2.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.2.7.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.2.7.2 Market size, by application, 2017-2030 (USD Million)
8.2.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.2.7.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.2.7.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
8.2.7.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.2.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.2.7.4 Market size, by technology, 2017-2030 (USD Million)
8.3 Europe
8.3.1 Market size, by country, 2017-2030 (USD Million)
8.3.2 Market size, by product, 2017-2030 (USD Million)
8.3.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.3 Market size, by application, 2017-2030 (USD Million)
8.3.3.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.3.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.4 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.5 Market size, by technology, 2017-2030 (USD Million)
8.3.6 Germany
8.3.6.1 Market size, by product, 2017-2030 (USD Million)
8.3.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.6.2 Market size, by application, 2017-2030 (USD Million)
8.3.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.6.4 Market size, by technology, 2017-2030 (USD Million)
8.3.7 UK
8.3.7.1 Market size, by product, 2017-2030 (USD Million)
8.3.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.7.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.7.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.7.2 Market size, by application, 2017-2030 (USD Million)
8.3.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.7.4 Market size, by technology, 2017-2030 (USD Million)
8.3.8 France
8.3.8.1 Market size, by product, 2017-2030 (USD Million)
8.3.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.8.2 Market size, by application, 2017-2030 (USD Million)
8.3.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.8.4 Market size, by technology, 2017-2030 (USD Million)
8.3.9 Spain
8.3.9.1 Market size, by product, 2017-2030 (USD Million)
8.3.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.9.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.9.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.9.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.9.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.9.2 Market size, by application, 2017-2030 (USD Million)
8.3.9.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.9.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.9.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.9.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.9.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.9.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.9.4 Market size, by technology, 2017-2030 (USD Million)
8.3.10 Italy
8.3.10.1 Market size, by product, 2017-2030 (USD Million)
8.3.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.10.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.10.2 Market size, by application, 2017-2030 (USD Million)
8.3.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.10.4 Market size, by technology, 2017-2030 (USD Million)
8.3.11 Turkey
8.3.11.1 Market size, by product, 2017-2030 (USD Million)
8.3.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.11.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.11.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.11.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.11.2 Market size, by application, 2017-2030 (USD Million)
8.3.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.11.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.11.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.11.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.11.4 Market size, by technology, 2017-2030 (USD Million)
8.3.12 Austria
8.3.12.1 Market size, by product, 2017-2030 (USD Million)
8.3.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.12.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.12.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.12.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.12.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.12.2 Market size, by application, 2017-2030 (USD Million)
8.3.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.12.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.12.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.12.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.12.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.12.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.12.4 Market size, by technology, 2017-2030 (USD Million)
8.3.13 Belgium
8.3.13.1 Market size, by product, 2017-2030 (USD Million)
8.3.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.13.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.13.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.13.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.13.2 Market size, by application, 2017-2030 (USD Million)
8.3.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.13.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.13.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.13.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.13.4 Market size, by technology, 2017-2030 (USD Million)
8.3.14 Bulgaria
8.3.14.1 Market size, by product, 2017-2030 (USD Million)
8.3.14.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.14.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.14.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.14.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.14.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.14.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.14.2 Market size, by application, 2017-2030 (USD Million)
8.3.14.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.14.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.14.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.14.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.14.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.14.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.14.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.14.4 Market size, by technology, 2017-2030 (USD Million)
8.3.15 Czech Republic
8.3.15.1 Market size, by product, 2017-2030 (USD Million)
8.3.15.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.15.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.15.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.15.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.15.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.15.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.15.2 Market size, by application, 2017-2030 (USD Million)
8.3.15.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.15.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.15.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.15.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.15.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.15.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.15.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.15.4 Market size, by technology, 2017-2030 (USD Million)
8.3.16 Denmark
8.3.16.1 Market size, by product, 2017-2030 (USD Million)
8.3.16.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.16.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.16.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.16.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.16.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.16.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.16.2 Market size, by application, 2017-2030 (USD Million)
8.3.16.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.16.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.16.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.16.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.16.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.16.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.16.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.16.4 Market size, by technology, 2017-2030 (USD Million)



List of Tables

8.3.17 Finland
8.3.17.1 Market size, by product, 2017-2030 (USD Million)
8.3.17.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.17.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.17.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.17.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.17.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.17.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.17.2 Market size, by application, 2017-2030 (USD Million)
8.3.17.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.17.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.17.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.17.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.17.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.17.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.17.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.17.4 Market size, by technology, 2017-2030 (USD Million)
8.3.18 Greece
8.3.18.1 Market size, by product, 2017-2030 (USD Million)
8.3.18.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.18.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.18.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.18.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.18.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.18.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.18.2 Market size, by application, 2017-2030 (USD Million)
8.3.18.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.18.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.18.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.18.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.18.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.18.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.18.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.18.4 Market size, by technology, 2017-2030 (USD Million)
8.3.19 Hungary
8.3.19.1 Market size, by product, 2017-2030 (USD Million)
8.3.19.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.19.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.19.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.19.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.19.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.19.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.19.2 Market size, by application, 2017-2030 (USD Million)
8.3.19.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.19.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.19.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.19.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.19.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.19.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.19.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.19.4 Market size, by technology, 2017-2030 (USD Million)
8.3.20 Ireland
8.3.20.1 Market size, by product, 2017-2030 (USD Million)
8.3.20.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.20.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.20.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.20.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.20.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.20.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.20.2 Market size, by application, 2017-2030 (USD Million)
8.3.20.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.20.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.20.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.20.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.20.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.20.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.20.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.20.4 Market size, by technology, 2017-2030 (USD Million)
8.3.21 Netherlands
8.3.21.1 Market size, by product, 2017-2030 (USD Million)
8.3.21.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.21.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.21.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.21.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.21.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.21.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.21.2 Market size, by application, 2017-2030 (USD Million)
8.3.21.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.21.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.21.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.21.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.21.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.21.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.21.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.21.4 Market size, by technology, 2017-2030 (USD Million)
8.3.22 Norway
8.3.22.1 Market size, by product, 2017-2030 (USD Million)
8.3.22.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.22.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.22.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.22.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.22.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.22.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.22.2 Market size, by application, 2017-2030 (USD Million)
8.3.22.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.22.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.22.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.22.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.22.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.22.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.22.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.22.4 Market size, by technology, 2017-2030 (USD Million)
8.3.23 Romania
8.3.23.1 Market size, by product, 2017-2030 (USD Million)
8.3.23.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.23.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.23.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.23.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.23.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.23.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.23.2 Market size, by application, 2017-2030 (USD Million)
8.3.23.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.23.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.23.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.23.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.23.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.23.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.23.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.23.4 Market size, by technology, 2017-2030 (USD Million)
8.3.24 Slovakia
8.3.24.1 Market size, by product, 2017-2030 (USD Million)
8.3.24.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.24.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.24.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.24.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.24.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.24.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.24.2 Market size, by application, 2017-2030 (USD Million)
8.3.24.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.24.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.24.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.24.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.24.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.24.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.24.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.24.4 Market size, by technology, 2017-2030 (USD Million)
8.3.25 Slovenia
8.3.25.1 Market size, by product, 2017-2030 (USD Million)
8.3.25.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.25.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.25.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.25.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.25.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.25.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.25.2 Market size, by application, 2017-2030 (USD Million)
8.3.25.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.25.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.25.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.25.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.25.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.25.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.25.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.25.4 Market size, by technology, 2017-2030 (USD Million)
8.3.26 Sweden
8.3.26.1 Market size, by product, 2017-2030 (USD Million)
8.3.26.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.26.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.26.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.26.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.26.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.26.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.26.2 Market size, by application, 2017-2030 (USD Million)
8.3.26.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.26.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.26.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.26.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.26.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.26.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.26.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.26.4 Market size, by technology, 2017-2030 (USD Million)
8.3.27 Switzerland
8.3.27.1 Market size, by product, 2017-2030 (USD Million)
8.3.27.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.3.27.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.3.27.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.3.27.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.3.27.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.3.27.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.3.27.2 Market size, by application, 2017-2030 (USD Million)
8.3.27.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.3.27.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.3.27.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.3.27.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.3.27.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.3.27.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.3.27.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.3.27.4 Market size, by technology, 2017-2030 (USD Million)
8.4 Asia Pacific
8.4.1 Market size, by country, 2017-2030 (USD Million)
8.4.2 Market size, by product, 2017-2030 (USD Million)
8.4.2.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.2.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.4.2.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.2.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.2.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.2.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.4.3 Market size, by application, 2017-2030 (USD Million)
8.4.3.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.3.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.3.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.3.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.3.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.3.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.4 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.5 Market size, by technology, 2017-2030 (USD Million)
8.4.6 China
8.4.6.1 Market size, by product, 2017-2030 (USD Million)
8.4.6.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.6.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.4.6.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.6.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.6.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.6.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.4.6.2 Market size, by application, 2017-2030 (USD Million)
8.4.6.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.6.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.6.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.6.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.6.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.6.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.6.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.6.4 Market size, by technology, 2017-2030 (USD Million)
8.4.7 Japan
8.4.7.1 Market size, by product, 2017-2030 (USD Million)
8.4.7.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.7.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.7.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.7.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.7.2 Market size, by application, 2017-2030 (USD Million)
8.4.7.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.7.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.7.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.7.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.7.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.7.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.7.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.7.4 Market size, by technology, 2017-2030 (USD Million)
8.4.8 India
8.4.8.1 Market size, by product, 2017-2030 (USD Million)
8.4.8.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.8.1.1.1 Market size, by interferon, 2017-2030 (USD Million)
8.4.8.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.8.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.8.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.8.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.4.8.2 Market size, by application, 2017-2030 (USD Million)
8.4.8.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.8.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.8.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.8.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.8.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.8.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.8.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.8.4 Market size, by technology, 2017-2030 (USD Million)
8.4.9 South Korea
8.4.9.1 Market size, by product, 2017-2030 (USD Million)
8.4.9.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.9.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.9.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.9.2 Market size, by application, 2017-2030 (USD Million)
8.4.9.2.1 Market size, by oncology, 2017-2030 (USD Million)
8.4.9.2.1.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.9.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.9.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.9.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.9.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.9.4 Market size, by technology, 2017-2030 (USD Million)
8.4.10 Australia
8.4.10.1 Market size, by product, 2017-2030 (USD Million)
8.4.10.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.10.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.10.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.10.1.2.2 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.10.1.2.3 Market size, by follitropin, 2017-2030 (USD Million)
8.4.10.2 Market size, by application, 2017-2030 (USD Million)
8.4.10.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.10.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.10.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.10.2.3 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.10.2.3.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.10.2.3.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.10.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.10.4 Market size, by technology, 2017-2030 (USD Million)
8.4.11 New Zealand
8.4.11.1 Market size, by product, 2017-2030 (USD Million)
8.4.11.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.11.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.11.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.11.2 Market size, by application, 2017-2030 (USD Million)
8.4.11.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.11.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.11.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.11.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.11.4 Market size, by technology, 2017-2030 (USD Million)
8.4.12 Singapore
8.4.12.1 Market size, by product, 2017-2030 (USD Million)
8.4.12.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.12.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.12.1.2.1 Market size, by monoclonal antibodies, 2017-2030 (USD Million)
8.4.12.2 Market size, by application, 2017-2030 (USD Million)
8.4.12.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.12.2.2 Market size, by autoimmune disease, 2017-2030 (USD Million)
8.4.12.2.2.1 Market size, by arthritis, 2017-2030 (USD Million)
8.4.12.2.2.2 Market size, by inflammatory bowel disease, 2017-2030 (USD Million)
8.4.12.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.12.4 Market size, by technology, 2017-2030 (USD Million)
8.4.13 Malaysia
8.4.13.1 Market size, by product, 2017-2030 (USD Million)
8.4.13.1.1 Market size, by recombinant non-glycosylated proteins, 2017-2030 (USD Million)
8.4.13.1.2 Market size, by recombinant glycosylated proteins, 2017-2030 (USD Million)
8.4.13.1.2.1 Market size, by erythropoietin, 2017-2030 (USD Million)
8.4.13.2 Market size, by application, 2017-2030 (USD Million)
8.4.13.2.1 Market size, by hematology, 2017-2030 (USD Million)
8.4.13.2.2 Market size, by oncology, 2017-2030 (USD Million)
8.4.13.2.2.1 Market size, by leukemia, 2017-2030 (USD Million)
8.4.13.3 Market size, by manufacturer, 2017-2030 (USD Million)
8.4.13.4 Market size, by technology, 2017-2030 (USD Million)
Chapter 9 Company Profiles
9.1 Competitive dashboard, 2021
9.2 Biocon Ltd
9.2.1 Business overview
9.2.2 Financial data
9.2.3 Product landscape
9.2.4 Strategic outlook
9.2.5 SWOT analysis
9.3 Sandoz
9.3.1 Business overview
9.3.2 Financial data
9.3.3 Product landscape
9.3.4 Strategic outlook
9.3.5 SWOT analysis
9.4 Viatris
9.4.1 Business overview
9.4.2 Financial data
9.4.3 Product landscape
9.4.4 Strategic outlook
9.4.5 SWOT analysis
9.5 Bio-Thera Solutions
9.5.1 Business overview
9.5.2 Financial data
9.5.3 Product landscape
9.5.4 Strategic outlook
9.5.5 SWOT analysis
9.6 Pfizer
9.6.1 Business overview
9.6.2 Financial data
9.6.3 Product landscape
9.6.4 Strategic outlook
9.6.5 SWOT analysis
9.7 Dr. Reddy’s Laboratories
9.7.1 Business overview
9.7.2 Financial data
9.7.3 Product landscape
9.7.4 Strategic outlook
9.7.5 SWOT analysis
9.8 Amgen Inc.
9.8.1 Business overview
9.8.2 Financial data
9.8.3 Product landscape
9.8.4 Strategic outlook
9.8.5 SWOT analysis
9.9 Teva Pharmaceuticals
9.9.1 Business overview
9.9.2 Financial data
9.9.3 Product landscape
9.9.4 Strategic outlook
9.9.5 SWOT analysis
9.10 Fresenius Kabi
9.10.1 Business overview
9.10.2 Financial data
9.10.3 Product landscape
9.10.4 Strategic outlook
9.10.5 SWOT analysis
9.11 Coherus Biosciences
9.11.1 Business overview
9.11.2 Financial data
9.11.3 Product landscape
9.11.4 Strategic outlook
9.11.5 SWOT analysis
9.12 Apobiologix
9.12.1 Business overview
9.12.2 Financial data
9.12.3 Product landscape
9.12.4 Strategic outlook
9.12.5 SWOT analysis
9.13 Biocad
9.13.1 Business overview
9.13.2 Financial data
9.13.3 Product landscape
9.13.4 Strategic outlook
9.13.5 SWOT analysis
9.14 Intas Pharma
9.14.1 Business overview
9.14.2 Financial data
9.14.3 Product landscape
9.14.4 Strategic outlook
9.14.5 SWOT analysis
9.15 Reliance Life Sciences
9.15.1 Business overview
9.15.2 Financial data
9.15.3 Product landscape
9.15.4 Strategic outlook
9.15.5 SWOT analysis
9.16 Celltrion
9.16.1 Business overview
9.16.2 Financial data
9.16.3 Product landscape
9.16.4 Strategic outlook
9.16.5 SWOT analysis
9.17 Zydus Cadila
9.17.1 Business overview
9.17.2 Financial data
9.17.3 Product landscape
9.17.4 Strategic outlook
9.17.5 SWOT analysis
9.18 Lupin Pharma
9.18.1 Business overview
9.18.2 Financial data
9.18.3 Product landscape
9.18.4 Strategic outlook
9.18.5 SWOT analysis
9.19 Samsung Bioepis
9.19.1 Business overview
9.19.2 Financial data
9.19.3 Product landscape
9.19.4 Strategic outlook
9.19.5 SWOT analysis